Apogee Therapeutics (APGE) Cash & Current Investments (2022 - 2026)

Apogee Therapeutics (APGE) has reported Cash & Current Investments for 5 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 106.48% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 106.48% YoY), while the FY2025 annual figure was $730.2 million, up 40.25% from the prior year.
• Cash & Current Investments advanced to $1.1 billion in Q1 2026 per APGE's latest filing, from $730.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.1 billion in Q1 2026 and bottomed at $5.0 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $498.2 million across 5 years, with a median of $517.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Current Investments jumped 2414.46% — and 2025, when it sank 37.11%.
• Apogee Therapeutics' Cash & Current Investments stood at $151.9 million in 2022, then surged by 160.36% to $395.5 million in 2023, then soared by 31.66% to $520.7 million in 2024, then jumped by 40.25% to $730.2 million in 2025, then soared by 45.15% to $1.1 billion in 2026.
• Business Quant data shows APGE's Cash & Current Investments at $1.1 billion in Q1 2026, $730.2 million in Q4 2025, and $527.3 million in Q3 2025.